

pioglitazone (Actos[®])

No. 115/04

Takeda

Summary of Advice

9 August 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

Advice: following a full submission.

Pioglitazone (Actos[®]) is not recommended for use within NHS Scotland as monotherapy for patients with type 2 diabetes mellitus.

It is one of two peroxisome proliferator-activated receptor- γ agonists recently marketed in the UK for this indication. In controlling blood glucose, its mid range and maximum doses were non-inferior to standard sulphonylurea therapies. The economic case for pioglitazone has not been demonstrated.

Professor David H Lawson
Chairman